Dexpanthenol Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

Dexpanthenol Pharma Grade API is the enantiopure D-isomer of panthenol, CAS 81-13-0, molecular formula C9H19NO4, and molar mass 205.25 g/mol. The substance is supplied as a clear, viscous, hygroscopic liquid rather than a crystalline powder, and this physical form defines the handling, adsorption, granulation, and parenteral processing routes used in tablet, capsule, granule, and injectable manufacture. The pharmacopoeial release specification includes an assay range of 98.0% to 102.0% on an anhydrous basis, water content ≤2.0% by semi-micro Karl Fischer titration, refractive index 1.495–1.502 at 20 °C, and specific optical rotation in the positive D-enantiomer range. The product is packaged in 25 kg or 50 kg HDPE drums with an LDPE liner under a nitrogen overlay to limit water uptake and oxidative drift after first opening.

Because the API is liquid at controlled room temperature, material transfer from storage to compounding vessels is performed through heated lines or jacketed drums at 30–35 °C, with positive nitrogen pressure to prevent hygroscopic water gain. The product is not milled or micronized. For oral solid dosage forms, particle-size control is therefore transferred to the granulate or adsorbate rather than being applied to the API itself. Direct-compression tablets and hard capsules are manufactured after adsorbing Dexpanthenol onto porous carriers such as silicified microcrystalline cellulose, maltodextrin, or colloidal silicon dioxide. The maximum practical loading is determined by the oil-absorption capacity of the carrier; loadings of 20% to 40% w/w are typical, but the resulting blend must be tested for flow index, moisture content, and compressibility before tableting.

Why does enantiomeric purity control both potency and parenteral compatibility?

Dexpanthenol differs from racemic panthenol in that the monograph controls optical rotation, which for Dexpanthenol is specified in the range +29.0° to +32.0° measured at 20 °C with a 5% aqueous solution. Racemic panthenol would fall near zero rotation and would contain 50% of the L-enantiomer, which does not exhibit the same provitamin B5 activity. The free-alcohol structure also differentiates Dexpanthenol from calcium pantothenate, the crystalline calcium salt of pantothenic acid. Calcium pantothenate has a molar mass of 476.53 g/mol and contains 8.4% w/w calcium, whereas Dexpanthenol has a molar mass of 205.25 g/mol and contains no metal counterion. In injectable admixtures containing phosphate or bicarbonate buffers, the absence of calcium avoids calcium phosphate precipitation, a documented incompatibility for calcium-containing B-complex formulations.

For oral solid dosage forms, the liquid state of Dexpanthenol is the primary formulation difference. It cannot be directly filled into a tablet die as a neat liquid without prior processing; instead it is dissolved into the granulating fluid or adsorbed onto a porous carrier. This property makes it suitable for wet granulation and liquid-filled hard capsules, whereas calcium pantothenate is often preferred when a free-flowing dry powder is required for direct blending. In parenteral manufacture, the free-alcohol structure permits high aqueous solubility without co-solvents, reducing the need for polysorbate or propylene glycol in the finished solution.

In a high-shear granulation suite using a top-spray fluid-bed granulator, Dexpanthenol is dissolved in purified water or a purified water–ethanol mixture and sprayed onto a substrate of microcrystalline cellulose or maltodextrin. Process settings reported in production campaigns commonly include inlet air temperature 45–60 °C, product temperature 35–45 °C, spray rate 5–20 g/min per kg of substrate, and atomizing air pressure 1.0–2.0 bar. After spraying, the granulate is dried to a loss-on-drying endpoint of ≤2.0%, milled through a 0.8–1.0 mm conical screen, and compressed on a rotary tablet press with a precompression station and main compression force of 8–18 kN. Tablet friability below 0.5% and disintegration within 15 minutes in purified water at 37 °C are typical release targets under Ph. Eur. 2.9.7 and Ph. Eur. 2.9.1. The liquid API creates a batch-to-batch handling requirement: if the dosing vessel is left open in ambient air at relative humidity above 60%, water content increases and can fail the monograph limit. Closed transfer under nitrogen is therefore part of the manufacturing procedure.

Release specifications for oral solid, granule, and injectable application routes

The following release test matrix is applied to the API. Injectable grades add bacterial endotoxin and bioburden testing; oral grades may omit endotoxin unless requested by a downstream dossier.

The assay is corrected for water content. The microbial tests are harmonized with the finished-product dossier; a non-sterile API cannot be released for injection without terminal sterilization or sterile filtration downstream.

For liquid-filled hard capsules, Dexpanthenol can be filled directly or after dilution with a hydrophilic excipient such as PEG 400 or glycerol macrogol. Capsule filling on a dosing-disc or piston pump machine requires the fill mass to be controlled to ±2%; the liquid temperature is held at 35 °C to maintain viscosity uniformity. Gelatin capsules exposed to high-moisture liquid fills may soften, and hydroxypropyl methylcellulose capsules are often selected for compatibility. Published data for this specific configuration is limited, and each fill formulation is subjected to capsule shell compatibility testing at 40 °C/75% RH for 6 months under ICH Q1A conditions.

When terminal sterilization imposes limits on solution holding time and excipient selection

For injectable compounding, Dexpanthenol is dissolved in Water for Injection to the required strength, commonly 250 mg/mL in licensed compounding formulas. The bulk solution is filtered through a 0.22 µm sterilizing-grade polyvinylidene difluoride membrane and filled into ampoules or vials. Terminal moist-heat sterilization is performed at 121 °C with an F0 value of ≥8 minutes, provided that the container-closure system is validated for autoclaving. The solution must not be processed through prolonged steam-in-place cycles because the amide group is susceptible to hydrolysis under strongly acidic or strongly alkaline conditions. A pH in the neutral-to-mildly acidic range is maintained, and holding time after filtration is limited to the validated period. No organic co-solvent is required for solubility, and no calcium or phosphate is introduced by the API. If the finished product contains phosphate buffer from other actives, the formulation scientist must perform a compatibility screen because Dexpanthenol itself will not precipitate with phosphate, whereas calcium pantothenate would produce calcium phosphate precipitation.

For ampoule filling, the liquid can be purged with nitrogen before sealing to reduce oxidative headspace degradation. Residual oxygen in the headspace is typically controlled to ≤2.0% v/v. The filled ampoule is sterilized in a water cascade autoclave; glass ampoules are preferred over plastic because of the autoclave load pressure. Post-sterilization leaker tests are performed by methylene blue dye ingress under vacuum. The API supplier cannot guarantee these finished-product results; they are a function of the aseptic and terminal sterilization process.

The calculation for the API endotoxin limit follows Ph. Eur. 5.1.10; for a 500 mg dose in a 70 kg patient the threshold is 0.7 EU/mg, while many dossiers apply an in-house limit of 0.25 EU/mg to provide process margin. Endotoxin testing is repeated on the final container because the API limit alone does not guarantee that the manufacturing line is depyrogenated.

Comparative data for Dexpanthenol, racemic panthenol, and calcium pantothenate

The table below summarizes the differences that determine formulation choice. Racemic panthenol is not typically used in pharmaceutical oral or injectable products because the monograph specification for Dexpanthenol is enantiomer-specific.

This comparison is based on physicochemical properties and standard B-vitamin compatibility screening, not on clinical efficacy data. For a specific formulation, the choice is confirmed by forced-degradation studies and excipient compatibility testing under ICH Q1A and ICH Q1B conditions.

Granule release testing includes sieve analysis across 0.125 mm, 0.250 mm, 0.500 mm, and 1.000 mm screens, bulk density by tapped density apparatus, and loss on drying. In one standard configuration, the target tapped density is 0.45–0.65 g/mL and the Carr index is maintained below 25 to avoid press hopper segregation. After compression, tablet hardness of 80–120 N and friability ≤0.8% are used as process controls. These values are not API monograph requirements; they are manufacturing-site specifications derived from the finished-product dossier.

Dexpanthenol is compatible with most common tablet excipients, but in binary mixtures with high-surface-area silicas the liquid can be adsorbed to the point of poor powder flow. When the blend is compressed, ejection force can increase if insufficient glidant is present. Lubrication with magnesium stearate at 0.5–1.0% w/w and colloidal silicon dioxide at 0.2–0.5% w/w is typical, but the exact amounts are determined by compressibility and flow studies. Over-lubrication is avoided because it can reduce tablet tensile strength.

In practice, the operational boundary for Dexpanthenol is the combination of hygroscopicity and high viscosity at room temperature. Bulk storage must be in tight containers under nitrogen at 15–25 °C and protected from light; the manufacturer’s label should follow the storage statement of the current Ph. Eur. monograph for substances for pharmaceutical use. Transfer lines are heated to 30–35 °C to reduce pressure drop. If the API is held in a compounding vessel for more than the validated short period, routine in-process water content and refractive index checks are required before release. The product should not be exposed to strong acids, strong bases, or prolonged oxidizing conditions because these accelerate amide hydrolysis or oxidation. For injectable applications, bacterial endotoxin and bioburden release testing are not optional additions; they are part of the route-specific control strategy. For oral tablet and capsule manufacture, the same liquid grade can be used when the process includes adsorption onto a solid carrier or dissolution into the granulating fluid, and the granulate rather than the API is subjected to particle-size and flowability testing.